Inhibition of ATP hydrolysis as a key regulator of temozolomide resistance and migratory phenotype of glioblastoma cells

Biochem Biophys Res Commun. 2022 Apr 23:601:24-30. doi: 10.1016/j.bbrc.2022.02.062. Epub 2022 Feb 22.

Abstract

Glioblastoma (GBM) is the most lethal among malignant gliomas. The tumor invasiveness and therapy-resistance are important clinical hallmarks. Growing evidence emphasizes the purinergic signaling contributing to tumor growth. Here we exposed a potential role of extracellular ATPase activity as a key regulator of temozolomide cytotoxicity and the migration process in GBM cells. The inhibition of ATP hydrolysis was able to improve the impact of temozolomide, causing arrest mainly in S and G2 phases of the cell cycle, leading M059J and U251 cells to apoptosis. In addition to eradicating GBM cells, ATP hydrolysis exhibited a potential to modulate the invasive phenotype and the expression of proteins involved in cell migration and epithelial-to-mesenchymal-like transition in a 3D culture model. Finally, we suggest the ATPase activity as a key target to decline temozolomide resistance and the migratory phenotype in GBM cells.

Keywords: ATP; CD39; Ectoenzyme; Glioblastoma; Migration; Temozolomide.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenosine Triphosphatases / genetics
  • Adenosine Triphosphate / pharmacology
  • Antineoplastic Agents, Alkylating / pharmacology
  • Antineoplastic Agents, Alkylating / therapeutic use
  • Brain Neoplasms* / pathology
  • Cell Line, Tumor
  • Cell Proliferation
  • Drug Resistance, Neoplasm
  • Glioblastoma* / pathology
  • Humans
  • Hydrolysis
  • Phenotype
  • Temozolomide / pharmacology
  • Temozolomide / therapeutic use

Substances

  • Antineoplastic Agents, Alkylating
  • Adenosine Triphosphate
  • Adenosine Triphosphatases
  • Temozolomide